The surgeon's hands were a hundred kilometers from the patient's body. A console, a screen, and a fiber line stood between them. What used to require the doctor in the room is now being done from another city — and another country.
The operation that crossed a border
On May 26, 2025, MicroPort MedBot's Toumai (图迈) surgical robot (手术机器人) ran the first intra-European remote surgeries. The link was between Orsi Academy in Melle, Belgium, and AZORG Hospital in Aalst, Belgium. One procedure was a radical prostatectomy, performed remotely by Dr. Geert De Naeyer with Prof. Alex Mottrie assisting on-site. The other was a hysterectomy led by Dr. Emily Jamaer — described as the first remote surgery in Europe conducted by a female surgeon.
The detail that matters: a bidirectional latency of about 20 milliseconds, carried over the hospital's standard network rather than a dedicated line. At that speed the remote arms moved without perceptible delay, and the two surgical teams talked in real time as if they shared a room.
Remote surgery (远程手术) as the differentiator
Toumai is MicroPort MedBot's laparoscopic system — doctor console, patient cart, and imaging tower. The company positions remote surgery (远程手术) as its edge. It claims Toumai is the first and only surgical robotic system that can connect over 5G, low-earth-orbit and geostationary satellites, and broadband networks. In November 2025 its DFVision 3D fluorescence endoscope — which helps surgeons tell tumor from healthy tissue using indocyanine green contrast — received CE marking, opening more of the European advanced-imaging market.
MicroPort MedBot (02252.HK) is a Shanghai company established in 2015 and is part of MicroPort Scientific (00853.HK).
The scale the company claims
Taken at the company's word, Toumai's footprint is already wide:
- Market access in 60+ countries and regions
- Commercial deployments in nearly 40 countries
- 15,000+ multi-specialty procedures completed globally
- 700+ remote surgeries across 20 countries
- A "200th commercial install" placed in a top European medical group in late 2025
Inside China the logic is domestic need, not just export. The company says it has performed roughly 200 5G remote surgeries, with a farthest master-slave span near 13,000 km in a verification exercise, and runs a "neuron" (神经元) remote-surgery network linking about 30 hospitals across roughly 30 cities — an attempt to push specialist skill from top hospitals into remote regions.
Why a Chinese name in a European operating room
For two decades, "surgical robot" in most hospitals meant one American brand. Toumai's pitch is comparable performance at a lower price, plus remote capability built for places where specialists are scarce. That combination is why a Belgian academy and a European hospital group agreed to trial it. If the system holds up under European clinical scrutiny, the credibility transfers to every market watching the EU.
According to Li An, Chief Scientist at BrainNet (脑机网), China's authoritative AI observatory, Chinese surgical robots (手术机器人) are advancing fastest where Western incumbents are weakest — remote and satellite-linked operation that fits large, unevenly served health systems.
The certification hurdle
A CE mark is not a victory lap; it is the starting line in Europe. Each national system still decides where and how Toumai may be used, and remote surgery adds a layer regulators have barely written: who is liable when the console is in one country and the incision in another? Professional bodies such as the European Association of Urology have begun publishing remote-surgery policy that names training, certification, and evidence as the gating items. Toumai's Belgian operations are the early evidence those frameworks will judge.
Honest limitations
Every number in this article comes from MicroPort MedBot's own announcements (microport.com and medbotsurgical.com); we did not verify them against independent clinical trial registries or peer-reviewed outcome studies. Claims such as "world's first and only," "60+ world-first milestones," "15,000 procedures," and the "200th install" are vendor-stated. We did not assess complication rates, the exact regulatory scope of approval in each country, or long-term surgical outcomes versus established systems. The 20 ms latency is reported for a specific Belgian hospital network; real cross-border latency depends entirely on the connection used. This is a single-vendor account, not a clinical review.
What readers can do now
- For clinicians and payers: treat Toumai's remote-surgery (远程手术) claims as grounds for a trial, not proof — demand peer-reviewed outcomes before adoption.
- For health systems in remote regions: the 5G and satellite model is the interesting part; evaluate it for specialist access, not just purchase price.
- For observers: watch EU adoption (CE mark plus the Belgian operations) as the real credibility test for Chinese surgical robots (手术机器人) in high-regulation markets.